Search
Collaborationsbreadcrumb separatorINSIGHT
INSIGHT

 

INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) is an HIV/AIDS clinical trials network funded in 2006 by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health. INSIGHT has been conducting studies in 46 countries worldwide.
 
INSIGHT consists of four international coordinating centres (ICCs) - CHIP is one of them.
The ultimate vision of INSIGHT is: “Reducing the global burden of HIV and other infectious diseases”. INSIGHT is in a position to respond rapidly to the challenges that endemic and emerging infectious diseases present through its globally-located investigators and its diverse sites that are poised to conduct research and quickly disseminate evidence-based clinical management strategies. INSIGHT’s mission is to: “To define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network.”
INSIGHT is organized with an Executive Committee, primarily responsible for securing network funding that enhances and sustains the efficient and effective organization. The daily business is maintained through the Scientific Steering Committee (SSC) and the Operational Steering Committee (OSC). Jens Lundgren is chairing the SSC, with responsibility for ensuring outstanding research productivity within the INSIGHT network and identification and development of new research projects aligned with the INSIGHT mission. The Operational Steering Committee (OSC) is responsible for oversight of protocol teams; maintaining quality and performance and developing cross-network procedures. 
 
Find more information on the INSIGHT website.

Studies run by the INSIGHT network:
 

Ongoing studies

 

START (Strategic Timing of AntiRetroviral Treatment) details on study

 

FLU 003 Plus (Respiratory Virus Hospitalization Study, INSIGHT Protocol No. 003) details on study

 

ACTT (Adaptive COVID-19 Treatment Trial) details on study

 

ICOS (International SARS-CoV-2 Infection Observational Study) details on study

 

Completed studies

 

FLU 002 Plus (Respiratory Virus Outpatient Study, INSIGHT Protocol No. 002) details on study

 

FLU-IVIG (Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study, INSIGHT Protocol No. 006 ) details on study

 

C.diff (An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treated for C. Difficile Infections, INSIGHT Protocol No. 007) details on study

 

ESPRIT (Evaluation of Subcutaneous Proleukin® in a Randomized International Trial) details on study

 

SILCAAT (Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy) details on study

 

STALWART (Study of Aldesleukin with and without Antiretroviral Therapy) details on study

 

SMART (Strategies for Management of Anti-Retroviral Therapy) details on study